Difference between revisions of "Vascular sarcoma"
m |
(Pomalidomide added) Tag: visualeditor |
||
Line 1: | Line 1: | ||
{| class="wikitable" style="text-align:center; width:50%;" | {| class="wikitable" style="text-align:center; width:50%;" | ||
− | !colspan="2 | + | ! colspan="2" style="color:white; font-size:125%; background-color:#08519c" align="center" |'''Section editor''' |
|- | |- | ||
− | |style="background-color:#F0F0F0"|[[File:Elizabethdavis2.jpg|frameless|upright=0.3|center]] | + | | style="background-color:#F0F0F0" |[[File:Elizabethdavis2.jpg|frameless|upright=0.3|center]] |
|<big>[[User:Elizabethdavis|Elizabeth J. Davis, MD]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/ejdavis25 ejdavis25] | |<big>[[User:Elizabethdavis|Elizabeth J. Davis, MD]]<br>Vanderbilt University<br>Nashville, TN</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/ejdavis25 ejdavis25] | ||
|- | |- | ||
Line 15: | Line 15: | ||
=Guidelines= | =Guidelines= | ||
==[http://www.esmo.org/ ESMO]== | ==[http://www.esmo.org/ ESMO]== | ||
+ | |||
*[http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://www.ncbi.nlm.nih.gov/pubmed/25210080 PubMed] | *[http://annonc.oxfordjournals.org/content/25/suppl_3/iii102.full.pdf+html Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014)] [https://www.ncbi.nlm.nih.gov/pubmed/25210080 PubMed] | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
+ | |||
*[https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma] | *[https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma] | ||
*[https://www.nccn.org/professionals/physician_gls/pdf/kaposi.pdf NCCN Guidelines - AIDS-related Kaposi Sarcoma] | *[https://www.nccn.org/professionals/physician_gls/pdf/kaposi.pdf NCCN Guidelines - AIDS-related Kaposi Sarcoma] | ||
Line 31: | Line 33: | ||
===Regimen {{#subobject:c663b6|Variant=1}}=== | ===Regimen {{#subobject:c663b6|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[http://annonc.oxfordjournals.org/content/24/1/257.long Agulnik et al. 2013] | |[http://annonc.oxfordjournals.org/content/24/1/257.long Agulnik et al. 2013] | ||
− | |style="background-color:#91cf61"|Phase II | + | | style="background-color:#91cf61" |Phase II |
|- | |- | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1 | *[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1 | ||
Line 44: | Line 47: | ||
===References=== | ===References=== | ||
− | # Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. [http://annonc.oxfordjournals.org/content/24/1/257.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22910841 PubMed] | + | |
+ | #Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. [http://annonc.oxfordjournals.org/content/24/1/257.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22910841 PubMed] | ||
==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== | ==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== | ||
Line 53: | Line 57: | ||
===Regimen {{#subobject:ebf64d|Variant=1}}=== | ===Regimen {{#subobject:ebf64d|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[http://jco.ascopubs.org/content/26/32/5269.long Penel et al. 2008 (ANGIOTAX)] | |[http://jco.ascopubs.org/content/26/32/5269.long Penel et al. 2008 (ANGIOTAX)] | ||
− | |style="background-color:#91cf61"|Phase II | + | | style="background-color:#91cf61" |Phase II |
|- | |- | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15 | ||
====Supportive medications==== | ====Supportive medications==== | ||
+ | |||
*[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | *[[Dexamethasone (Decadron)]] 8 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | ||
*[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | *[[Cimetidine (Tagamet)]] 200 mg IV once per day on days 1, 8, 15, prior to [[Paclitaxel (Taxol)]] | ||
Line 72: | Line 78: | ||
===References=== | ===References=== | ||
− | # '''ANGIOTAX:''' Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. [http://jco.ascopubs.org/content/26/32/5269.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18809609 PubMed] | + | |
+ | #'''ANGIOTAX:''' Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. [http://jco.ascopubs.org/content/26/32/5269.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18809609 PubMed] | ||
=Hemangioendothelioma, all lines of therapy= | =Hemangioendothelioma, all lines of therapy= | ||
Line 88: | Line 95: | ||
===Regimen {{#subobject:097d6d|Variant=1}}=== | ===Regimen {{#subobject:097d6d|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://ascopubs.org/doi/abs/10.1200/JCO.1984.2.10.1115 Laubenstein et al. 1984] | |[https://ascopubs.org/doi/abs/10.1200/JCO.1984.2.10.1115 Laubenstein et al. 1984] | ||
Line 96: | Line 103: | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Doxorubicin (Adriamycin)]] | *[[Doxorubicin (Adriamycin)]] | ||
*[[Bleomycin (Blenoxane)]] | *[[Bleomycin (Blenoxane)]] | ||
*[[Vinblastine (Velban)]] | *[[Vinblastine (Velban)]] | ||
+ | |||
===References=== | ===References=== | ||
− | # Laubenstein LJ, Krigel RL, Odajnyk CM, Hymes KB, Friedman-Kien A, Wernz JC, Muggia FM. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol. 1984 Oct;2(10):1115-20. [https://ascopubs.org/doi/abs/10.1200/JCO.1984.2.10.1115 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6208343 PubMed] | + | |
+ | #Laubenstein LJ, Krigel RL, Odajnyk CM, Hymes KB, Friedman-Kien A, Wernz JC, Muggia FM. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol. 1984 Oct;2(10):1115-20. [https://ascopubs.org/doi/abs/10.1200/JCO.1984.2.10.1115 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6208343 PubMed] | ||
==ABV (Vincristine) {{#subobject:4531b5|Regimen=1}}== | ==ABV (Vincristine) {{#subobject:4531b5|Regimen=1}}== | ||
Line 110: | Line 120: | ||
===Variant #1, 10/15/1 {{#subobject:b47ecf|Variant=1}}=== | ===Variant #1, 10/15/1 {{#subobject:b47ecf|Variant=1}}=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 25%"|Comparator | + | ! style="width: 25%" |Comparator |
− | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[http://jco.ascopubs.org/content/14/8/2353.long Gill et al. 1996] | |[http://jco.ascopubs.org/content/14/8/2353.long Gill et al. 1996] | ||
− | |style="background-color:#1a9851"|Phase III (C) | + | | style="background-color:#1a9851" |Phase III (C) |
|[[#Daunorubicin_liposomal_monotherapy|Liposomal daunorubicin]] | |[[#Daunorubicin_liposomal_monotherapy|Liposomal daunorubicin]] | ||
− | |style="background-color:#ffffbf"|Seems not superior | + | | style="background-color:#ffffbf" |Seems not superior |
|- | |- | ||
|} | |} | ||
Line 124: | Line 134: | ||
''Gill et al. 1996 described doses but did not clearly say in the paper when these drugs were given, but this schedule is assumed based on the Northfelt et al. 1998 ABV regimen. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.'' | ''Gill et al. 1996 described doses but did not clearly say in the paper when these drugs were given, but this schedule is assumed based on the Northfelt et al. 1998 ABV regimen. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.'' | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup> IV once on day 1 | *[[Doxorubicin (Adriamycin)]] 10 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Bleomycin (Blenoxane)]] 15 units IV once on day 1 | *[[Bleomycin (Blenoxane)]] 15 units IV once on day 1 | ||
Line 129: | Line 140: | ||
====Supportive medications==== | ====Supportive medications==== | ||
+ | |||
*"No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator" | *"No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator" | ||
Line 135: | Line 147: | ||
===Variant #2, 20/10/1 {{#subobject:d923d9|Variant=1}}=== | ===Variant #2, 20/10/1 {{#subobject:d923d9|Variant=1}}=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 25%"|Comparator | + | ! style="width: 25%" |Comparator |
− | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[http://jco.ascopubs.org/content/16/7/2445.long Northfelt et al. 1998] | |[http://jco.ascopubs.org/content/16/7/2445.long Northfelt et al. 1998] | ||
− | |style="background-color:#1a9851"|Phase III (C) | + | | style="background-color:#1a9851" |Phase III (C) |
|[[#Doxorubicin_pegylated_liposomal_monotherapy|Pegylated liposomal doxorubicin]] | |[[#Doxorubicin_pegylated_liposomal_monotherapy|Pegylated liposomal doxorubicin]] | ||
− | |style="background-color:#d73027"|Inferior ORR | + | | style="background-color:#d73027" |Inferior ORR |
|- | |- | ||
|} | |} | ||
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.'' | ''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.'' | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Doxorubicin (Adriamycin)]] 20 mg/m<sup>2</sup> IV once on day 1 | *[[Doxorubicin (Adriamycin)]] 20 mg/m<sup>2</sup> IV once on day 1 | ||
*[[Bleomycin (Blenoxane)]] 10 mg/m<sup>2</sup> IV once on day 1 | *[[Bleomycin (Blenoxane)]] 10 mg/m<sup>2</sup> IV once on day 1 | ||
Line 153: | Line 166: | ||
====Supportive medications==== | ====Supportive medications==== | ||
+ | |||
*"Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators." | *"Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators." | ||
Line 158: | Line 172: | ||
===References=== | ===References=== | ||
− | # Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. [http://jco.ascopubs.org/content/14/8/2353.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8708728 PubMed] | + | |
− | # Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. [http://jco.ascopubs.org/content/16/7/2445.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9667262 PubMed] | + | #Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. [http://jco.ascopubs.org/content/14/8/2353.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8708728 PubMed] |
+ | #Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. [http://jco.ascopubs.org/content/16/7/2445.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9667262 PubMed] | ||
==Bevacizumab monotherapy {{#subobject:25316e|Regimen=1}}== | ==Bevacizumab monotherapy {{#subobject:25316e|Regimen=1}}== | ||
Line 168: | Line 183: | ||
===Regimen {{#subobject:48507a|Variant=1}}=== | ===Regimen {{#subobject:48507a|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383119/ Uldrick et al. 2012] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383119/ Uldrick et al. 2012] | ||
− | |style="background-color:#91cf61"|Phase II | + | | style="background-color:#91cf61" |Phase II |
|- | |- | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Bevacizumab (Avastin)]] as follows: | *[[Bevacizumab (Avastin)]] as follows: | ||
**Loading: 15 mg/kg IV once as a loading dose; start regular therapy 7 days later after this loading dose | **Loading: 15 mg/kg IV once as a loading dose; start regular therapy 7 days later after this loading dose | ||
Line 181: | Line 197: | ||
====Supportive medications==== | ====Supportive medications==== | ||
+ | |||
*"Antihypertensive therapy was initiated for systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg persisting for more than 1 week or for systolic blood pressure greater than 210 mmHg or diastolic blood pressure greater than 120 mmHg at any time." | *"Antihypertensive therapy was initiated for systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg persisting for more than 1 week or for systolic blood pressure greater than 210 mmHg or diastolic blood pressure greater than 120 mmHg at any time." | ||
*"HIV-positive patients with CD4 count of less than 200 cells/µL received Pneumocystis jiroveci prophylaxis." | *"HIV-positive patients with CD4 count of less than 200 cells/µL received Pneumocystis jiroveci prophylaxis." | ||
Line 190: | Line 207: | ||
===References=== | ===References=== | ||
− | # Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012 May 1;30(13):1476-83. Epub 2012 Mar 19. [http://jco.ascopubs.org/content/30/13/1476.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383119/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22430271 PubMed] | + | |
+ | #Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012 May 1;30(13):1476-83. Epub 2012 Mar 19. [http://jco.ascopubs.org/content/30/13/1476.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383119/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22430271 PubMed] | ||
==Daunorubicin liposomal monotherapy {{#subobject:92db30|Regimen=1}}== | ==Daunorubicin liposomal monotherapy {{#subobject:92db30|Regimen=1}}== | ||
Line 199: | Line 217: | ||
===Regimen {{#subobject:95ce2a|Variant=1}}=== | ===Regimen {{#subobject:95ce2a|Variant=1}}=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 25%"|Comparator | + | ! style="width: 25%" |Comparator |
− | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lancet/article/PII0140-6736(93)91147-E/fulltext Presant et al. 1993] | |[https://www.thelancet.com/journals/lancet/article/PII0140-6736(93)91147-E/fulltext Presant et al. 1993] | ||
Line 210: | Line 228: | ||
|- | |- | ||
|[http://jco.ascopubs.org/content/14/8/2353.long Gill et al. 1996] | |[http://jco.ascopubs.org/content/14/8/2353.long Gill et al. 1996] | ||
− | |style="background-color:#1a9851"|Phase III (E-RT) | + | | style="background-color:#1a9851" |Phase III (E-RT) |
|[[#ABV|ABV]] | |[[#ABV|ABV]] | ||
− | |style="background-color:#ffffbf"|Seems not superior | + | | style="background-color:#ffffbf" |Seems not superior |
|- | |- | ||
|} | |} | ||
''Note: Gill et al. 1996 stopped treatment if CR was achieved.'' | ''Note: Gill et al. 1996 stopped treatment if CR was achieved.'' | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Daunorubicin liposomal (DaunoXome)]] 40 mg/m<sup>2</sup> IV over 30 to 60 minutes once on day 1 | *[[Daunorubicin liposomal (DaunoXome)]] 40 mg/m<sup>2</sup> IV over 30 to 60 minutes once on day 1 | ||
====Supportive medications==== | ====Supportive medications==== | ||
+ | |||
*"No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator" | *"No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator" | ||
Line 225: | Line 245: | ||
===References=== | ===References=== | ||
− | # Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, Presant J. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet. 1993 May 15;341(8855):1242-3. [https://www.thelancet.com/journals/lancet/article/PII0140-6736(93)91147-E/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8098393 PubMed] | + | |
− | # Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. [http://jco.ascopubs.org/content/14/8/2353.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8708728 PubMed] | + | #Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, Presant J. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet. 1993 May 15;341(8855):1242-3. [https://www.thelancet.com/journals/lancet/article/PII0140-6736(93)91147-E/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8098393 PubMed] |
+ | #Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. [http://jco.ascopubs.org/content/14/8/2353.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8708728 PubMed] | ||
==Doxorubicin pegylated liposomal monotherapy {{#subobject:a880c2|Regimen=1}}== | ==Doxorubicin pegylated liposomal monotherapy {{#subobject:a880c2|Regimen=1}}== | ||
Line 236: | Line 257: | ||
===Variant #1, q2wk {{#subobject:6a33ec|Variant=1}}=== | ===Variant #1, q2wk {{#subobject:6a33ec|Variant=1}}=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 25%"|Comparator | + | ! style="width: 25%" |Comparator |
− | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://ascopubs.org/doi/abs/10.1200/JCO.1998.16.2.683 Stewart et al. 1998] | |[https://ascopubs.org/doi/abs/10.1200/JCO.1998.16.2.683 Stewart et al. 1998] | ||
− | |style="background-color:#1a9851"|Phase III (E) | + | | style="background-color:#1a9851" |Phase III (E) |
|BV | |BV | ||
− | |style="background-color:#1a9850"|Superior ORR | + | | style="background-color:#1a9850" |Superior ORR |
|- | |- | ||
|[http://jco.ascopubs.org/content/16/7/2445.long Northfelt et al. 1998] | |[http://jco.ascopubs.org/content/16/7/2445.long Northfelt et al. 1998] | ||
− | |style="background-color:#1a9851"|Phase III (E) | + | | style="background-color:#1a9851" |Phase III (E) |
|[[#ABV|ABV]] | |[[#ABV|ABV]] | ||
− | |style="background-color:#1a9850"|Superior ORR | + | | style="background-color:#1a9850" |Superior ORR |
|- | |- | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Pegylated liposomal doxorubicin (Doxil)]] 20 mg/m<sup>2</sup> IV over 30 minutes once on day 1 | *[[Pegylated liposomal doxorubicin (Doxil)]] 20 mg/m<sup>2</sup> IV over 30 minutes once on day 1 | ||
====Supportive medications==== | ====Supportive medications==== | ||
+ | |||
*"Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators." | *"Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators." | ||
Line 262: | Line 285: | ||
===Variant #2, q3wk {{#subobject:6a33ha|Variant=1}}=== | ===Variant #2, q3wk {{#subobject:6a33ha|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 50%"|Study | + | ! style="width: 50%" |Study |
− | !style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://ascopubs.org/doi/abs/10.1200/JCO.1995.13.4.914 Harrison et al. 1995] | |[https://ascopubs.org/doi/abs/10.1200/JCO.1995.13.4.914 Harrison et al. 1995] | ||
Line 270: | Line 293: | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Pegylated liposomal doxorubicin (Doxil)]] 20 mg/m<sup>2</sup> IV once on day 1 | *[[Pegylated liposomal doxorubicin (Doxil)]] 20 mg/m<sup>2</sup> IV once on day 1 | ||
Line 275: | Line 299: | ||
===References=== | ===References=== | ||
− | # Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1995 Apr;13(4):914-20. [https://ascopubs.org/doi/abs/10.1200/JCO.1995.13.4.914 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7707119 PubMed] | + | |
− | # Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ; International Pegylated Liposomal Doxorubicin Study Group. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 1998 Feb;16(2):683-91. [https://ascopubs.org/doi/abs/10.1200/JCO.1998.16.2.683 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9469358 PubMed] | + | #Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1995 Apr;13(4):914-20. [https://ascopubs.org/doi/abs/10.1200/JCO.1995.13.4.914 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7707119 PubMed] |
− | # Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. [http://jco.ascopubs.org/content/16/7/2445.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9667262 PubMed] | + | #Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ; International Pegylated Liposomal Doxorubicin Study Group. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 1998 Feb;16(2):683-91. [https://ascopubs.org/doi/abs/10.1200/JCO.1998.16.2.683 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9469358 PubMed] |
+ | #Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. [http://jco.ascopubs.org/content/16/7/2445.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9667262 PubMed] | ||
==Etoposide monotherapy {{#subobject:9b5ac9|Regimen=1}}== | ==Etoposide monotherapy {{#subobject:9b5ac9|Regimen=1}}== | ||
Line 286: | Line 311: | ||
===Variant #1, 8 cycles {{#subobject:a25060|Variant=1}}=== | ===Variant #1, 8 cycles {{#subobject:a25060|Variant=1}}=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 25%"|Comparator | + | ! style="width: 25%" |Comparator |
− | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://academic.oup.com/cid/article-abstract/67/2/251/4819203 Hosseinipour et al. 2018 (REACT-KS)] | |[https://academic.oup.com/cid/article-abstract/67/2/251/4819203 Hosseinipour et al. 2018 (REACT-KS)] | ||
Line 298: | Line 323: | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Etoposide (Vepesid)]] 50 mg PO once per day on days 1 to 7 | *[[Etoposide (Vepesid)]] 50 mg PO once per day on days 1 to 7 | ||
Line 304: | Line 330: | ||
===Variant #2, indefinite {{#subobject:abc832|Variant=1}}=== | ===Variant #2, indefinite {{#subobject:abc832|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 50%"|Study | + | ! style="width: 50%" |Study |
− | !style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[http://jco.ascopubs.org/content/20/15/3236.long Evans et al. 2002] | |[http://jco.ascopubs.org/content/20/15/3236.long Evans et al. 2002] | ||
− | |style="background-color:#91cf61"|Phase II | + | | style="background-color:#91cf61" |Phase II |
|- | |- | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Etoposide (Vepesid)]] 50 mg PO once per day on days 1 to 7 | *[[Etoposide (Vepesid)]] 50 mg PO once per day on days 1 to 7 | ||
'''14-day cycles''' | '''14-day cycles''' | ||
===References=== | ===References=== | ||
− | # Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002 Aug 1;20(15):3236-41. [http://jco.ascopubs.org/content/20/15/3236.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12149296 PubMed] | + | |
− | # '''REACT-KS:''' Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, Martínez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB; A5264/AMC-067 REACT-KS Team. As-needed vs immediate etoposide chemotherapy in combination with antiretroviral therapy for mild-to-moderate AIDS-associated Kaposi sarcoma in resource-limited settings: A5264/AMC-067 randomized clinical trial. Clin Infect Dis. 2018 Jul 2;67(2):251-260. [https://academic.oup.com/cid/article-abstract/67/2/251/4819203 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29365083 PubMed] | + | #Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002 Aug 1;20(15):3236-41. [http://jco.ascopubs.org/content/20/15/3236.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12149296 PubMed] |
+ | #'''REACT-KS:''' Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, Martínez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB; A5264/AMC-067 REACT-KS Team. As-needed vs immediate etoposide chemotherapy in combination with antiretroviral therapy for mild-to-moderate AIDS-associated Kaposi sarcoma in resource-limited settings: A5264/AMC-067 randomized clinical trial. Clin Infect Dis. 2018 Jul 2;67(2):251-260. [https://academic.oup.com/cid/article-abstract/67/2/251/4819203 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29365083 PubMed] | ||
==Interferon alfa-2a monotherapy {{#subobject:abca9e|Regimen=1}}== | ==Interferon alfa-2a monotherapy {{#subobject:abca9e|Regimen=1}}== | ||
Line 326: | Line 354: | ||
===Regimen {{#subobject:bdacd4|Variant=1}}=== | ===Regimen {{#subobject:bdacd4|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)90810-0/fulltext de Wit et al. 1988] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)90810-0/fulltext de Wit et al. 1988] | ||
− | |style="background-color:#91cf61"|Phase II | + | | style="background-color:#91cf61" |Phase II |
|- | |- | ||
|} | |} | ||
====Immunotherapy==== | ====Immunotherapy==== | ||
+ | |||
*[[Interferon alfa-2a (Roferon-A)]] | *[[Interferon alfa-2a (Roferon-A)]] | ||
+ | |||
===References=== | ===References=== | ||
− | # de Wit R, Schattenkerk JK, Boucher CA, Bakker PJ, Veenhof KH, Danner SA. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1214-7. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)90810-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2903953 PubMed] | + | |
+ | #de Wit R, Schattenkerk JK, Boucher CA, Bakker PJ, Veenhof KH, Danner SA. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1214-7. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)90810-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2903953 PubMed] | ||
==Interferon alfa-2b monotherapy {{#subobject:8uga9e|Regimen=1}}== | ==Interferon alfa-2b monotherapy {{#subobject:8uga9e|Regimen=1}}== | ||
Line 345: | Line 376: | ||
===Regimen {{#subobject:ygagd4|Variant=1}}=== | ===Regimen {{#subobject:ygagd4|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19870201)59:3%2B%3C620::AID-CNCR2820591309%3E3.0.CO;2-5 Volberding et al. 1987] | |[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19870201)59:3%2B%3C620::AID-CNCR2820591309%3E3.0.CO;2-5 Volberding et al. 1987] | ||
− | |style="background-color:#91cf61"|Phase II (RT) | + | | style="background-color:#91cf61" |Phase II (RT) |
|- | |- | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140673688908112/fulltext Lane et al. 1988] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140673688908112/fulltext Lane et al. 1988] | ||
− | |style="background-color:#91cf61"|Non-randomized (RT) | + | | style="background-color:#91cf61" |Non-randomized (RT) |
|- | |- | ||
|} | |} | ||
====Immunotherapy==== | ====Immunotherapy==== | ||
+ | |||
*[[Interferon alfa-2b (Intron-A)]] | *[[Interferon alfa-2b (Intron-A)]] | ||
+ | |||
===References=== | ===References=== | ||
− | # Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A). Cancer. 1987 Feb 1;59(3 Suppl):620-5. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19870201)59:3%2B%3C620::AID-CNCR2820591309%3E3.0.CO;2-5 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3492260 PubMed] | + | |
− | # Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, Deyton L, Metcalf JA, Baseler M, Salzman N, Quinnan G, Fauci AS. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1218-22. [https://www.thelancet.com/journals/lancet/article/PIIS0140673688908112/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2903954 PubMed] | + | #Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A). Cancer. 1987 Feb 1;59(3 Suppl):620-5. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19870201)59:3%2B%3C620::AID-CNCR2820591309%3E3.0.CO;2-5 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3492260 PubMed] |
+ | #Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, Deyton L, Metcalf JA, Baseler M, Salzman N, Quinnan G, Fauci AS. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1218-22. [https://www.thelancet.com/journals/lancet/article/PIIS0140673688908112/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2903954 PubMed] | ||
==Paclitaxel monotherapy {{#subobject:df8a9e|Regimen=1}}== | ==Paclitaxel monotherapy {{#subobject:df8a9e|Regimen=1}}== | ||
Line 368: | Line 402: | ||
===Regimen {{#subobject:bd95c4|Variant=1}}=== | ===Regimen {{#subobject:bd95c4|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(95)92654-2/fulltext Saville et al. 1995 (CA139-174)] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(95)92654-2/fulltext Saville et al. 1995 (CA139-174)] | ||
− | |style="background-color:#91cf61"|Phase II (RT) | + | | style="background-color:#91cf61" |Phase II (RT) |
|- | |- | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV over 3 hours once on day 1 | *[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV over 3 hours once on day 1 | ||
Line 381: | Line 416: | ||
===References=== | ===References=== | ||
− | # '''CA139-174:''' Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, Yarchoan R. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(95)92654-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7603142 PubMed] | + | |
+ | #'''CA139-174:''' Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, Yarchoan R. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(95)92654-2/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7603142 PubMed] | ||
==Placebo== | ==Placebo== | ||
Line 390: | Line 426: | ||
===Regimen=== | ===Regimen=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 25%"|Comparator | + | ! style="width: 25%" |Comparator |
− | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://ascopubs.org/doi/full/10.1200/JCO.2005.11.043 Noy et al. 2005] | |[https://ascopubs.org/doi/full/10.1200/JCO.2005.11.043 Noy et al. 2005] | ||
Line 403: | Line 439: | ||
''No active antineoplastic treatment.'' | ''No active antineoplastic treatment.'' | ||
===References=== | ===References=== | ||
− | # Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. [https://ascopubs.org/doi/full/10.1200/JCO.2005.11.043 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15598977 PubMed] | + | |
+ | #Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. [https://ascopubs.org/doi/full/10.1200/JCO.2005.11.043 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15598977 PubMed] | ||
+ | |||
+ | == Pomalidomide == | ||
+ | |||
+ | === Regimen === | ||
+ | {| class="wikitable" style="width: 50%; text-align:center;" | ||
+ | ! style="width: 25%" |Study | ||
+ | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://ascopubs.org/doi/10.1200/JCO.2016.69.3812 Polizzotto et al. 2016] | ||
+ | | style="background-color:#91cf61" |Non-randomized | ||
+ | |- | ||
+ | |} | ||
+ | ====Chemotherapy==== | ||
+ | |||
+ | * [[Pomalidomide (Pomalyst)]] 5 mg PO once per day for days 1-21 | ||
+ | ** Dose adjustment to 3 mg allowed if 5mg dose is not tolerated | ||
+ | |||
+ | ==== Supportive medications ==== | ||
+ | |||
+ | * [[Aspirin]] 81 mg PO once per day (unless contraindicated) | ||
+ | |||
+ | ==== 28-day cycles ==== | ||
+ | |||
+ | ===References=== | ||
+ | |||
+ | #Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Maldarelli F, Goncalves PH, Figg WD, Steinberg SM, Yarchoan R. Pomalidomide for symptomatic Kaposi's Sarcoma in people with and without HIV infection: A Phase I/II Study. J Clin Oncol. 2016 Dec;34(34):4125-4131 [https://ascopubs.org/doi/10.1200/JCO.2016.69.3812 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/?term=27863194 PubMed] | ||
[[Category:Vascular sarcoma regimens]] | [[Category:Vascular sarcoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Soft tissue sarcomas]] | [[Category:Soft tissue sarcomas]] |
Revision as of 17:27, 24 October 2019
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN ejdavis25 |
0 regimens on this page
0 variants on this page
|
Guidelines
ESMO
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed
NCCN
Angiosarcoma, all lines of therapy
Bevacizumab monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Agulnik et al. 2013 | Phase II |
Chemotherapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
References
- Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. link to original article contains verified protocol PubMed
Paclitaxel monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Penel et al. 2008 (ANGIOTAX) | Phase II |
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
Supportive medications
- Dexamethasone (Decadron) 8 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 200 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Dexchlorpheniramine (Polaramine) 5 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- "Standard antiemetics (mainly Metoclopramide (Reglan)) were prescribed as clinically indicated by the treating physician"
28-day cycle for 6 cycles
References
- ANGIOTAX: Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. link to original article contains verified protocol PubMed
Hemangioendothelioma, all lines of therapy
Hemangiopericytoma (solitary fibrous tumor), all lines of therapy
Kaposi sarcoma, all lines of therapy
ABV (Vinblastine)
back to top |
ABV: Adriamycin (Doxorubicin), Bleomycin, Vinblastine
Regimen
Study | Evidence |
---|---|
Laubenstein et al. 1984 | Non-randomized |
Chemotherapy
References
- Laubenstein LJ, Krigel RL, Odajnyk CM, Hymes KB, Friedman-Kien A, Wernz JC, Muggia FM. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol. 1984 Oct;2(10):1115-20. link to original article PubMed
ABV (Vincristine)
back to top |
ABV: Adriamycin (Doxorubicin), Bleomycin, Vincristine
Variant #1, 10/15/1
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Gill et al. 1996 | Phase III (C) | Liposomal daunorubicin | Seems not superior |
Gill et al. 1996 described doses but did not clearly say in the paper when these drugs were given, but this schedule is assumed based on the Northfelt et al. 1998 ABV regimen. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
- Doxorubicin (Adriamycin) 10 mg/m2 IV once on day 1
- Bleomycin (Blenoxane) 15 units IV once on day 1
- Vincristine (Oncovin) 1 mg IV once on day 1
Supportive medications
- "No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator"
14-day cycle for at least 2 cycles until complete remission
Variant #2, 20/10/1
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Northfelt et al. 1998 | Phase III (C) | Pegylated liposomal doxorubicin | Inferior ORR |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
- Doxorubicin (Adriamycin) 20 mg/m2 IV once on day 1
- Bleomycin (Blenoxane) 10 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1 mg IV once on day 1
Supportive medications
- "Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators."
14-day cycle for up to 6 cycles
References
- Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. link to original article contains verified protocol PubMed
- Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. link to original article contains verified protocol PubMed
Bevacizumab monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Uldrick et al. 2012 | Phase II |
Chemotherapy
- Bevacizumab (Avastin) as follows:
- Loading: 15 mg/kg IV once as a loading dose; start regular therapy 7 days later after this loading dose
- Cycle 1 onwards: 15 mg/kg IV once on day 1
Supportive medications
- "Antihypertensive therapy was initiated for systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg persisting for more than 1 week or for systolic blood pressure greater than 210 mmHg or diastolic blood pressure greater than 120 mmHg at any time."
- "HIV-positive patients with CD4 count of less than 200 cells/µL received Pneumocystis jiroveci prophylaxis."
- "Mycobacterium avium prophylaxis was considered if CD4 count was less than 75 cells/µL."
- Patients with HIV/AIDS continued HAART
- Filgrastim (Neupogen) "used as clinically indicated"
21-day cycles
References
- Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012 May 1;30(13):1476-83. Epub 2012 Mar 19. link to original article contains verified protocol link to PMC article PubMed
Daunorubicin liposomal monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Presant et al. 1993 | Phase II | ||
Gill et al. 1996 | Phase III (E-RT) | ABV | Seems not superior |
Note: Gill et al. 1996 stopped treatment if CR was achieved.
Chemotherapy
- Daunorubicin liposomal (DaunoXome) 40 mg/m2 IV over 30 to 60 minutes once on day 1
Supportive medications
- "No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator"
14-day cycles
References
- Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, Presant J. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet. 1993 May 15;341(8855):1242-3. link to original article PubMed
- Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. link to original article contains verified protocol PubMed
Doxorubicin pegylated liposomal monotherapy
back to top |
Variant #1, q2wk
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Stewart et al. 1998 | Phase III (E) | BV | Superior ORR |
Northfelt et al. 1998 | Phase III (E) | ABV | Superior ORR |
Chemotherapy
- Pegylated liposomal doxorubicin (Doxil) 20 mg/m2 IV over 30 minutes once on day 1
Supportive medications
- "Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators."
14-day cycle for up to 6 cycles
Variant #2, q3wk
Study | Evidence |
---|---|
Harrison et al. 1995 | Phase II (RT) |
Chemotherapy
- Pegylated liposomal doxorubicin (Doxil) 20 mg/m2 IV once on day 1
21-day cycles
References
- Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1995 Apr;13(4):914-20. link to original article contains protocol PubMed
- Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ; International Pegylated Liposomal Doxorubicin Study Group. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 1998 Feb;16(2):683-91. link to original article contains protocol PubMed
- Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. link to original article contains verified protocol PubMed
Etoposide monotherapy
back to top |
Variant #1, 8 cycles
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Hosseinipour et al. 2018 (REACT-KS) | Phase III (C) | As-needed Etoposide | Seems not superior |
Chemotherapy
- Etoposide (Vepesid) 50 mg PO once per day on days 1 to 7
14-day cycle for up to 8 cycles
Variant #2, indefinite
Study | Evidence |
---|---|
Evans et al. 2002 | Phase II |
Chemotherapy
- Etoposide (Vepesid) 50 mg PO once per day on days 1 to 7
14-day cycles
References
- Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002 Aug 1;20(15):3236-41. link to original article contains verified protocol PubMed
- REACT-KS: Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, Martínez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB; A5264/AMC-067 REACT-KS Team. As-needed vs immediate etoposide chemotherapy in combination with antiretroviral therapy for mild-to-moderate AIDS-associated Kaposi sarcoma in resource-limited settings: A5264/AMC-067 randomized clinical trial. Clin Infect Dis. 2018 Jul 2;67(2):251-260. link to original article PubMed
Interferon alfa-2a monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
de Wit et al. 1988 | Phase II |
Immunotherapy
References
- de Wit R, Schattenkerk JK, Boucher CA, Bakker PJ, Veenhof KH, Danner SA. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1214-7. link to original article PubMed
Interferon alfa-2b monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Volberding et al. 1987 | Phase II (RT) |
Lane et al. 1988 | Non-randomized (RT) |
Immunotherapy
References
- Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A). Cancer. 1987 Feb 1;59(3 Suppl):620-5. link to original article PubMed
- Lane HC, Kovacs JA, Feinberg J, Herpin B, Davey V, Walker R, Deyton L, Metcalf JA, Baseler M, Salzman N, Quinnan G, Fauci AS. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1218-22. link to original article PubMed
Paclitaxel monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Saville et al. 1995 (CA139-174) | Phase II (RT) |
Chemotherapy
- Paclitaxel (Taxol) 135 mg/m2 IV over 3 hours once on day 1
21-day cycles
References
- CA139-174: Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S, Yarchoan R. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet. 1995 Jul 1;346(8966):26-8. link to original article contains protocol PubMed
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Noy et al. 2005 | Phase III (C) | IM862 | Seems to have superior TTP |
No active antineoplastic treatment.
References
- Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed
Pomalidomide
Regimen
Study | Evidence |
---|---|
Polizzotto et al. 2016 | Non-randomized |
Chemotherapy
- Pomalidomide (Pomalyst) 5 mg PO once per day for days 1-21
- Dose adjustment to 3 mg allowed if 5mg dose is not tolerated
Supportive medications
- Aspirin 81 mg PO once per day (unless contraindicated)
28-day cycles
References
- Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Maldarelli F, Goncalves PH, Figg WD, Steinberg SM, Yarchoan R. Pomalidomide for symptomatic Kaposi's Sarcoma in people with and without HIV infection: A Phase I/II Study. J Clin Oncol. 2016 Dec;34(34):4125-4131 link to original article PubMed